RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc., (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored clinical study of the company’s drug IPLEX™ in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS).
